Abstracts tagged "myositis and pediatric rheumatology"

Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 282 • 2012 ACR/ARHP Annual Meeting
Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children
Gulnara Mamyrova¹, James D. Katz¹, Robert V. Jones², Peter A. Lachenbruch³, Mona Shah³, Olcay Y. Jones¹, Anupam Chahal¹, Seema Agrawal¹, Frederick W. Miller³, Lisa G. Rider³ and the Childhood Myositis Heterogeneity Group⁴, ¹Rheumatology, George Washington University, Washington, DC, ²Pathology, George Washington University, Washington, DC, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Niehs, NIH, Bethesda, MD
Background/Purpose: We examined demographic, clinical and laboratory features of juvenile polymyositis (JPM) and muscular dystrophy in children to improve classification of these two conditions. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].